Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antiviral Activity of ABI-H3733 in Chronic Hepatitis B
NCT05414981Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ABI-H3733 with Placebo (2 arms). Primary endpoint: Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs, and abnormal laboratory results up to 56 days. Started Aug 2022; status: completed.
02
Drugs
ABI-H3733
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05414981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414981.